logo
  

ExOne Reveals Management Changes; David Burns Reassigned As Global Sales Head

The ExOne Co. (XONE), a provider of 3D printing machines and printed products to industrial customers, said it is implementing management changes effective immediately to provide direct and centralized operational control and reporting to its Chairman and Chief Executive, Kent Rockwell.

ExOne's Chairman and Chief Executive commented, "Our management team is critical to the success of the company, and as our company evolves, it is critical that we advance and promote the right leadership. These managers have made key contributions to the current success of the company, and I believe that the expansion of their responsibilities will help guide the company to achieve its operating and strategic goals."

David Burns, formerly ExOne's president and chief operating officer, is now the Global Head of Sales focusing his sole efforts on the expansion of the company's sales initiatives. Burns has had extensive career experience in manufacturing sales management in global regions, including Japan, and has been a key figure in implementing ExOne's worldwide sale organization. He resigned as ExOne's President and Chief Operating Officer, effective December 18, 2014.

Rick Lucas, ExOne's Chief Technology Officer, would directly report to the CEO, Kent Rockwell. Tim Pierce, ExOne's United States Chief Operating Officer, manages the firm's five North American production service centers in the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT